QUOTE AND NEWS
Business Wire  Jan 28  Comment 
Abiomed, Inc. (NASDAQ: ABMD) announced today that on Thursday, February 4, 2010, the Company will release financial results for the third quarter of fiscal 2010. The Company will host a conference call to discuss the results on Thursday, February 4,
Business Wire  Jan 27  Comment 
Abiomed, Inc. (NASDAQ: ABMD) (“Abiomed”), a leading provider of breakthrough heart support technologies designed for heart recovery, today announced a strategic partnership with Opsens (TSX VENTURE EXCHANGE: OPS) (“Opsens”), a leading
Business Wire  Jan 25  Comment 
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the webcast of a Impella® 2.5 procedure featuring new product enhancements at Mount Sinai Medical Center. The webcast is now available and
Stock Blog Hub  Jan 11  Comment 
Abiomed, Inc. (ABMD) reported preliminary results for the third quarter of fiscal 2010. Total revenues were roughly $22.8 million, an increase of 32% year over year and were at a record high. The company will report full results for the third...
Business Wire  Jan 7  Comment 
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies designed for heart recovery, today announced preliminary third quarter fiscal 2010 revenue of approximately $22.8 million, up 32% compared to revenue of $17.3
Business Wire  Jan 6  Comment 
Abiomed, Inc. (NASDAQ: ABMD) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 28th Annual JP Morgan Healthcare Conference on Wednesday, January 13, 2010 at 4:30 p.m. PT/ 7:30 p.m. ET. The
Business Wire  Dec 17  Comment 
Results from the Europella registry, evaluating the safety and feasibility of the Abiomed, Inc. (NASDAQ: ABMD) Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures have been published in the December
Business Wire  Dec 2  Comment 
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced availability of a webcast with results from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and
Stock Blog Hub  Nov 9  Comment 
Abiomed, Inc. (ABMD) reported fiscal second-quarter loss of 14 cents per share, considerably better than the Zacks Consensus Estimate of a loss of 21 cents. However, loss per share in the year-ago quarter was 8 cents. Total revenues in the...
StreetInsider.com  Nov 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Abiomed+%28ABMD%29+Posts+Q2+Loss+of+%240.21%2C+In-Line+with+Estimates/5077733.html for the full story.



Thank you for your suggestion
RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS
ABMD AT A GLANCE
 
 
 
 
 
 
 
 

Headquartered in Danvers, Massachusetts and founded in 1981, Abiomed Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products designed to assist or replace the pumping function of the failing heart. The company's strategy focuses on heart recovery as the goal for all acute cardiac attacks. Abiomed's products are designed to enable the heart to rest, heal and recover. The company's products can be used in a range of clinical settings, including by heart surgeons for patients in profound cardiogenic shock. Profound cardiogenic shock is starvation of the cells, or not enough blood flow to the organs as a result of an imbalance between oxygen supply and oxygen demand. Shock is a result of a weakened heart that is unable to pump blood as efficiently as it once did. Shock commonly occurs after a heart attack. The company's products can also be used by interventional cardiologists for patients who are in pre-shock or in need of prophylactic support in the cardiac catheterization lab (cath lab). The company has designed two FDA-approved products for heart recovery following acute events: the BVS 5000 biventricular support system (BVS) and the AB5000 circulatory support system (AB5000). There are two primary types of devices used in the cath lab and surgery suite for circulatory support for pre-shock and profound shock patients: intra-aortic balloons (IABs), an inflatable balloon inserted by a catheter that is used as an initial line of therapy in the cath lab or the surgery suite for patients with diminished heart function, and ventricular assist devices (VADs) that are mechanical devices which helps in the pumping function of the failing heart. To support the IAB, the company developed its iPulse multi-purpose console which also supports its AB5000 and BVS 5000 systems. The company also developed the AbioCor Implantable Replacement Heart for severe biventricular heart failure when chronic patients are ineligible for a heart transplant. In Europe, Abiomed offers the minimally invasive Impella Circulatory Support System.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki